Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · April 22, 2024

Outcomes of Treatment With Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa

The British Journal of Dermatology

 

Additional Info

The British Journal of Dermatology
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial
Br J Dermatol 2024 Apr 05;[EPub Ahead of Print], A Alavi, E Prens, AB Kimball, JW Frew, JG Krueger, S Mukhopadhyay, H Gao, U Ranganathan, NB Ivanoff, AC Hernandez Daly, CC Zouboulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading